Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-life data of abiraterone acetate and enzalutamide treatment in post-chemotherapy metastatic castration-resistant prostate cancer in Poland.
Sigorski D, Wilk M, Gawlik-Urban A, Sałek-Zań A, Kiszka J, Malik M, Czerko K, Kuć K, Szczylik C, Kubiatowski T, Cybulska-Stopa B, Filipczyk-Cisarż E, Bodnar L, Skoneczna I. Sigorski D, et al. Among authors: cybulska stopa b. Front Oncol. 2023 Apr 3;13:1108937. doi: 10.3389/fonc.2023.1108937. eCollection 2023. Front Oncol. 2023. PMID: 37077831 Free PMC article.
First-line treatment of advanced/metastatic melanoma with anti-PD-1 antibodies: multicenter experience in Poland.
Cybulska-Stopa B, Pacholczak-Madej R, Kamińska-Winciorek G, Ziętek M, Czarnecka AM, Piejko K, Galus Ł, Ziółkowska B, Kieszko S, Kempa-Kamińska N, Calik J, Rolski J, Sałek-Zań A, Gajewska-Wicher K, Drosik-Kwaśniewska A, Rogala P, Kubiatowski T, Suwiński R, Mackiewicz J, Rutkowski P. Cybulska-Stopa B, et al. Immunotherapy. 2021 Mar;13(4):297-307. doi: 10.2217/imt-2020-0217. Epub 2020 Dec 23. Immunotherapy. 2021. PMID: 33353420
Development of immunity-related adverse events correlates with baseline clinical factors, survival and response to anti-PD-1 treatment in patients with inoperable or metastatic melanoma.
Cybulska-Stopa B, Ziętek M, Czarnecka AM, Piejko K, Dziura R, Galus Ł, Ziółkowska B, Kieszko S, Kempa-Kamińska N, Calik J, Seredyńska J, Gądek K, Zemełka T, Teterycz P, Kubiatowski T, Suwiński R, Mackiewicz J, Rutkowski P. Cybulska-Stopa B, et al. J Dermatolog Treat. 2022 Jun;33(4):2168-2174. doi: 10.1080/09546634.2021.1937477. Epub 2021 Jun 14. J Dermatolog Treat. 2022. PMID: 34057374
Long-Term Outcomes of Targeted Therapy after First-Line Immunotherapy in BRAF-Mutated Advanced Cutaneous Melanoma Patients-Real-World Evidence.
Rogala P, Czarnecka AM, Cybulska-Stopa B, Ostaszewski K, Piejko K, Ziętek M, Dziura R, Rutkowska E, Galus Ł, Kempa-Kamińska N, Calik J, Sałek-Zań A, Zemełka T, Bal W, Kamycka A, Świtaj T, Kamińska-Winciorek G, Suwiński R, Mackiewicz J, Rutkowski P. Rogala P, et al. J Clin Med. 2022 Apr 17;11(8):2239. doi: 10.3390/jcm11082239. J Clin Med. 2022. PMID: 35456332 Free PMC article.
Long Term Results and Prognostic Biomarkers for Anti-PD1 Immunotherapy Used after BRAFi/MEKi Combination in Advanced Cutaneous Melanoma Patients.
Rogala P, Czarnecka AM, Cybulska-Stopa B, Ostaszewski K, Piejko K, Ziętek M, Dziura R, Rutkowska E, Galus Ł, Kempa-Kamińska N, Seredyńska J, Bal W, Kozak K, Surus-Hyla A, Kubiatowski T, Kamińska-Winciorek G, Suwiński R, Mackiewicz J, Rutkowski P. Rogala P, et al. Cancers (Basel). 2022 Apr 24;14(9):2123. doi: 10.3390/cancers14092123. Cancers (Basel). 2022. PMID: 35565255 Free PMC article.
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Powles T, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, Hajek J, Gurney H, Chang YH, Lee JL, Sarwar N, Thiery-Vuillemin A, Gross-Goupil M, Mahave M, Haas NB, Sawrycki P, Burgents JE, Xu L, Imai K, Quinn DI, Choueiri TK; KEYNOTE-564 Investigators. Powles T, et al. Lancet Oncol. 2022 Sep;23(9):1133-1144. doi: 10.1016/S1470-2045(22)00487-9. Lancet Oncol. 2022. PMID: 36055304 Free article. Clinical Trial.
Long-Term Real-World Outcomes and Safety of Vemurafenib and Vemurafenib + Cobimetinib Therapy in Patients with BRAF-Mutated Melanoma.
Piejko K, Cybulska-Stopa B, Ziętek M, Dziura R, Galus Ł, Kempa-Kamińska N, Ziółkowska B, Rutkowska E, Kopciński T, Kubiatowski T, Bal W, Suwiński R, Mackiewicz J, Kamińska-Winciorek G, Czarnecka AM, Rutkowski P. Piejko K, et al. Among authors: cybulska stopa b. Target Oncol. 2023 Mar;18(2):235-245. doi: 10.1007/s11523-023-00954-w. Epub 2023 Mar 11. Target Oncol. 2023. PMID: 36906728 Free PMC article.
Long-term clinical evidence of comparable efficacy and toxicity of nivolumab and pembrolizumab in advanced melanoma treatment.
Cybulska-Stopa B, Piejko K, Ostaszewski K, Dziura R, Galus Ł, Ziółkowska B, Kempa-Kamińska N, Ziętek M, Bal W, Kamycka A, Dudzisz-Śledź M, Kubiatowski T, Kamińska-Winciorek G, Suwiński R, Mackiewicz J, Czarnecka AM, Rutkowski P. Cybulska-Stopa B, et al. Melanoma Res. 2023 Jun 1;33(3):208-217. doi: 10.1097/CMR.0000000000000885. Epub 2023 Apr 3. Melanoma Res. 2023. PMID: 37015054
42 results